An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone

International Journal of Radiation Oncology Biology Physics

Volumn 62, Issue 5, 2005, Pages 1438-1443

  Yovino, Susannah ^a   Kwok, Young ^a   Krasna, Mark ^a   Bangalore, Madan ^a   Suntharalingam, Mohan ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Anemia; Non small cell lung cancer; Prognostic factors; Surgical resection

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; HEALTH RISKS; HEMOGLOBIN; HISTOLOGY; PATIENT TREATMENT; RADIOTHERAPY; REGRESSION ANALYSIS; SURGERY; TUMORS;

NON SMALL CELL LUNG CANCER; PROGNOSTIC FACTORS; SURVIVAL RATES;

PULMONARY DISEASES;

HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT SELECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 22144453499     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.12.038     Document Type: Article

References (56)

1. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. National Cancer Database, American College of Surgeons, 2001 benchmark reports. Available at http://web.facs.org. Accessed February 28, 2004.
3. P. Pairolero, D.E. Williams, E.J. Bergstralh Post-surgical stage I bronchogenic carcinoma Morbid implications of recurrent disease Ann Thorac Surg 38 1984 331 338
4. P. Thomas, L. Rubinstein Lung Cancer Study Group Cancer recurrence after resection T1N0 non-small-cell lung cancer Ann Thorac Surg 49 1990 242 246
5. N. Martini, B.J. Flehinger, M.B. Zaman Prospective study of 445 lung carcinomas with mediastinal lymph node metastases J Thorac Cardiovasc Surg 80 1980 390 397
6. C. Nieder, N. Andratschke, B. Jeremic Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer Anticancer Res 23 2003 5117 5123
7. G. Selvaggi, S. Novello, V. Torri Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer Ann Oncol 15 2004 28 32
8. A.M. Groeger, V. Esposito, A. De Luca Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers Histopathology 44 2004 54 63
9. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350;4:351-360.
10. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350;17:1713-1721.
11. Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer: Report of Cancer and Leukemia Group B Protocol 9633. 2004 ASCO Annual Meeting, abstract no. 7019.
12. Winton TL, Livingston R, Johnson D, et al. A prospective randomized trial of vinorelbine and cisplatin in completely resected stage IB and II non-small-cell lung cancer. 2004 ASCO Annual Meeting, abstract no. 7018.
13. M.T. van Rens, A.B. de la Riviere, H.R. Elbers Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA Chest 117 2000 374 379
14. A. Nissenson Anemia Not just an innocent bystander? Arch Intern Med 163 2003 1400 1405
15. L.B. Harrison, D. Shasha, P. Homel Prevalence of anemia in cancer patients undergoing radiotherapy Prognostic significance and treatment Oncology 63 Suppl. 2 2002 11 18
16. D.G. Grant, A. Hussain, D. Hurman Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy J Laryngol Otol 113 1999 829 833
17. J. Dunst, T. Kuhnt, H.G. Strauss Anemia in cervical cancers Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis Int J Radiat Oncol Biol Phys 56 2003 778 787
18. K. Munstedt, M. Kovacic, M. Zygmunt Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer Int J Oncol 23 2003 837 843
19. T. Wigren, H. Oksanen, P. Kellokumpu-Lehtinen A practical prognostic index for inoperable non-small-cell lung cancer J Cancer Res Clin Oncol 123 1997 259 266
20. J. Caro, M. Salas, A. Ward Anemia as an independent prognostic factor for survival in patients with cancer Cancer 91 2001 2214 2221
21. D.A. Weinstein, C.N. Roy, M.D. Fleming Inappropriate expression of hepcidin is associated with iron refractory anemia Implications for the anemia of chronic disease Blood 100 2002 3776 3781
22. L. Thomas, Y. Kwok, M. Edelman Management of paraneoplastic syndromes in lung cancer Curr Treat Option Oncol 5 2004 51 62
23. M.M. Elkind, R.W. Swain, T. Alescio Oxygen, nitrogen, recovery, and radiation therapy R.J. Shalek Cellular radiation biology 1965 Williams & Wilkins Baltimore 442 461
24. L. Harrison, M. Chadha, R. Hill, K. Hu Impact of tumor hypoxia and anemia on radiation therapy outcomes Oncologist 7 2002 492 508
25. A. Tomida, T. Tsuro Drug resistance mediated by cellular stress response to the microenvironment of solid tumors Anticancer Drug Res 14 1999 169 177
26. J.T. Erler, C.J. Cawthorne, K.J. Williams Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance Mol Cell Biol 24 2004 2875 2889
27. A. Dietz, V. Rudat, C. Conradt Prognostic value of hemoglobin level for primary radiochemotherapy of head-neck carcinomas HNO 48 2000 655 664
28. A.W. Fyles, M. Milosevic, M. Pintilie Anemia, hypoxia, and transfusion in patients with cervical cancer A review Radiother Oncol 57 2000 13 19
29. L. Harrison, M. Chadha, R. Hill Impact of tumor hypoxia and anemia on radiation therapy outcomes Oncologist 7 2002 492 508
30. G.M. Thomas Raising hemoglobin An opportunity for increasing survival? Oncology 63 Suppl. 2 2002 19 28
31. K. Sundfor, H. Lyng, U.L. Kongsgard Polarographic measurement of pO2 in cervix carcinoma Gynecol Oncol 64 1997 230 236
32. D. Kelleher, U. Matthiensen, O. Theuws Tumor oxygenation in anemic rats Effects of erythropoietin treatment versus red blood cell transfusion Acta Oncol 34 1995 379 384
33. R.S. Bush, R.D.T. Jenkins, W.E.C. Allt Definitive evidence for hypoxic cells influencing cure in cancer therapy Br J Cancer 37 Suppl. 3 1978 302 306
34. A. Osterborg, Y. Brandberg, V. Molotsova Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies J Clin Oncol 20 2002 2486-294
35. A.M. Olsson, J.H. Svensson, J. Sundstrom Erythropoietin treatment in metastatic breast cancer - effects on Hb, quality of life and need for transfusion Acta Oncol 41 2002 517 524
36. M. Boogaerts, B. Coiffier, C. Kainz Impact of epoetin beta on quality of life in patients with malignant disease Br J Cancer 88 2003 988 995
37. V. Brower Epoetin for cancer patients A boon or a danger? J Natl Cancer Inst 95 2003 1820 1821
38. M. Henke, R. Laszig, C. Rube Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy Randomised, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260
39. B. Leyland-Jones Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol 4 2003 459 460
40. RTOG member update, November 19, 2003. Available at: http://rtog.org/ members/board.html. Accessed May 16, 2004.
41. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Safety of erythropoietin receptor agonists in patients with cancer. Background information publication, Oncologic Drugs Advisory Committee Meeting, May 4, 2004.
42. G. Acs, P.J. Zhang, C.M. McGrath Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression Am J Pathol 162 2003 1789 1806
43. G. Acs, P. Acs, S.M. Beckwith Erythropoietin and erythropoietin receptor expression in human cancer Cancer Res 61 2001 3561 3565
44. S. Batra, N. Perelman, L.R. Luck Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival Lab Invest 83 2003 1477 1487
45. Y. Yasuda, Y. Fujita, T. Matsuo Erythropoietin regulates tumour growth of human malignancies Carcinogenesis 24 2003 1021 1029
46. D. Ribatti, A. Marzullo, B. Nico Erythropoietin as an angiogenic factor in gastric carcinoma Histopathology 42 2003 246 251
47. A. Takeshita, K. Shinjo, K. Naito Erythropoietin receptor in myelodysplastic syndrome and leukemia Leuk Lymphoma 43 2002 261 264
48. J.F. Bazan A novel family of growth factor receptors A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain Biochem Biophys Res Commun 164 1989 788 795
49. Z. Hochberg, T. Amit, M.B. Youdim The growth hormone binding protein as a paradigm of the erythropoietin superfamily of receptors Cell Signal 3 1991 85 91
50. V. Brower Epoetin for cancer patients A boon or a danger? J Natl Cancer Inst 95 2003 1820 1821
51. H. Yamaji, T. Iizasa, E. Koh Correlation between interleukin 6 production and tumor proliferation in non-small-cell lung cancer Cancer Immunol Immunother 53 2004 786 792
52. G.J. Caine, G.Y. Lip, P.S. Stonelake Platelet activation, coagulation, and angiogenesis in breast and prostate carcinoma Thromb Haemost 92 2004 185 190
53. E. Nemeth, S. Rivera, V. Gabayan IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin J Clin Invest 113 2004 1271 1276
54. T. Ganz Hepcidin, a key regulator of iron metabolism and mediator of anemia of chronic disease Blood 102 2003 783 788
55. A. Jazieh, M. Hussain, J. Howington Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer Ann Thorac Surg 70 2000 1168 1171
56. J. Lutterbach, R. Guttenberger Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx Int J Radiat Oncol Biol Phys 48 2000 1345 1350